Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 69
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Clin Gastroenterol Hepatol ; 19(5): 967-975.e2, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-32634624

RESUMEN

BACKGROUND & AIMS: Randomized trials have shown that biennial fecal occult blood test (FOBT) screening reduces mortality from colorectal cancer (CRC), but not overall mortality. Differences in benefit for men vs women, and by age, are unknown. We sought to evaluate long-term reduction in all-cause and CRC-specific mortality in men and women who comply with offered screening, and in different age groups, using individual participant data from 2 large randomized trials of biennial FOBT screening, compared with an intention to treat analysis. METHODS: We updated the CRC and all-cause mortality from the Danish CRC screening trial (n = 61,933) through 30 years of follow up and pooled individual participant data with individual 30-year follow-up data from the Minnesota Colon Cancer Control trial (n = 46,551). We compared the biennial screening groups to usual care (controls) in individuals 50-80 years old using Kaplan Meier estimates of relative risks and risk differences, adjusted for study differences in age, sex, and compliance. RESULTS: Through 30 years of follow up, there were 33,478 (71.9%) and 33,479 (72.2%) total deaths and 1023 (2.2%) and 1146 (2.5%) CRC deaths in the biennial screening (n = 46,553) and control groups (n = 46,358), respectively. Among compliers, biennial FOBT screening significantly reduced CRC mortality by 16% (relative risk [RR], 0.84; 95% CI, 0.74-0.96) and all-cause mortality by 2% (RR, 0.98; 95% CI, 0.97-0.99). Among compliers, the reduction in CRC mortality was larger for men (RR, 0.75; 95% CI, 0.62-0.90) than women (RR, 0.91; 95% CI, 0.75-1.09). The largest reduction in CRC mortality was in compliant men 60-69 years old (RR, 0.59; 95% CI, 0.42-0.81) and women 70 years and older (RR, 0.53; 95% CI, 0.30-0.94). CONCLUSIONS: Long-term CRC mortality outcomes of screening among compliers using biennial FOBT are sustained, with a statistically significant reduction in all-cause mortality. The reduction in CRC mortality is greater in men than women-the benefit in women lags that of men by about 10 years.


Asunto(s)
Neoplasias Colorrectales , Detección Precoz del Cáncer , Anciano , Anciano de 80 o más Años , Neoplasias Colorrectales/diagnóstico , Femenino , Humanos , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Sangre Oculta , Riesgo
3.
Cancer ; 122(6): 826-39, 2016 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-26828588

RESUMEN

BACKGROUND: New screening tests for colorectal cancer continue to emerge, but the evidence needed to justify their adoption in screening programs remains uncertain. METHODS: A review of the literature and a consensus approach by experts was undertaken to provide practical guidance on how to compare new screening tests with proven screening tests. RESULTS: Findings and recommendations from the review included the following: Adoption of a new screening test requires evidence of effectiveness relative to a proven comparator test. Clinical accuracy supported by programmatic population evaluation in the screening context on an intention-to-screen basis, including acceptability, is essential. Cancer-specific mortality is not essential as an endpoint provided that the mortality benefit of the comparator has been demonstrated and that the biologic basis of detection is similar. Effectiveness of the guaiac-based fecal occult blood test provides the minimum standard to be achieved by a new test. A 4-phase evaluation is recommended. An initial retrospective evaluation in cancer cases and controls (Phase 1) is followed by a prospective evaluation of performance across the continuum of neoplastic lesions (Phase 2). Phase 3 follows the demonstration of adequate accuracy in these 2 prescreening phases and addresses programmatic outcomes at 1 screening round on an intention-to-screen basis. Phase 4 involves more comprehensive evaluation of ongoing screening over multiple rounds. Key information is provided from the following parameters: the test positivity rate in a screening population, the true-positive and false-positive rates, and the number needed to colonoscope to detect a target lesion. CONCLUSIONS: New screening tests can be evaluated efficiently by this stepwise comparative approach.


Asunto(s)
Biomarcadores de Tumor/análisis , Neoplasias Colorrectales/diagnóstico , Detección Precoz del Cáncer/métodos , Estudios de Evaluación como Asunto , Tamizaje Masivo/métodos , Sangre Oculta , Proyectos de Investigación , Estudios de Casos y Controles , Ensayos Clínicos como Asunto , Colonoscopía , Reacciones Falso Positivas , Humanos , Guías de Práctica Clínica como Asunto/normas , Reproducibilidad de los Resultados , Tamaño de la Muestra
4.
N Engl J Med ; 369(12): 1106-14, 2013 Sep 19.
Artículo en Inglés | MEDLINE | ID: mdl-24047060

RESUMEN

BACKGROUND: In randomized trials, fecal occult-blood testing reduces mortality from colorectal cancer. However, the duration of the benefit is unknown, as are the effects specific to age and sex. METHODS: In the Minnesota Colon Cancer Control Study, 46,551 participants, 50 to 80 years of age, were randomly assigned to usual care (control) or to annual or biennial screening with fecal occult-blood testing. Screening was performed from 1976 through 1982 and from 1986 through 1992. We used the National Death Index to obtain updated information on the vital status of participants and to determine causes of death through 2008. RESULTS: Through 30 years of follow-up, 33,020 participants (70.9%) died. A total of 732 deaths were attributed to colorectal cancer: 200 of the 11,072 deaths (1.8%) in the annual-screening group, 237 of the 11,004 deaths (2.2%) in the biennial-screening group, and 295 of the 10,944 deaths (2.7%) in the control group. Screening reduced colorectal-cancer mortality (relative risk with annual screening, 0.68; 95% confidence interval [CI], 0.56 to 0.82; relative risk with biennial screening, 0.78; 95% CI, 0.65 to 0.93) through 30 years of follow-up. No reduction was observed in all-cause mortality (relative risk with annual screening, 1.00; 95% CI, 0.99 to 1.01; relative risk with biennial screening, 0.99; 95% CI, 0.98 to 1.01). The reduction in colorectal-cancer mortality was larger for men than for women in the biennial-screening group (P=0.04 for interaction). CONCLUSIONS: The effect of screening with fecal occult-blood testing on colorectal-cancer mortality persists after 30 years but does not influence all-cause mortality. The sustained reduction in colorectal-cancer mortality supports the effect of polypectomy. (Funded by the Veterans Affairs Merit Review Award Program and others.).


Asunto(s)
Neoplasias Colorrectales/mortalidad , Detección Precoz del Cáncer , Sangre Oculta , Adenoma/diagnóstico , Adenoma/mortalidad , Anciano , Anciano de 80 o más Años , Pólipos del Colon/diagnóstico , Pólipos del Colon/mortalidad , Pólipos del Colon/cirugía , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/prevención & control , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Análisis Multivariante , Riesgo , Factores Sexuales
6.
Crit Rev Toxicol ; 46(4): 279-331, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26761418

RESUMEN

Whether perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS), two widely used and biopersistent synthetic chemicals, are immunotoxic in humans is unclear. Accordingly, this article systematically and critically reviews the epidemiologic evidence on the association between exposure to PFOA and PFOS and various immune-related health conditions in humans. Twenty-four epidemiologic studies have reported associations of PFOA and/or PFOS with immune-related health conditions, including ten studies of immune biomarker levels or gene expression patterns, ten studies of atopic or allergic disorders, five studies of infectious diseases, four studies of vaccine responses, and five studies of chronic inflammatory or autoimmune conditions (with several studies evaluating multiple endpoints). Asthma, the most commonly studied condition, was evaluated in seven studies. With few, often methodologically limited studies of any particular health condition, generally inconsistent results, and an inability to exclude confounding, bias, or chance as an explanation for observed associations, the available epidemiologic evidence is insufficient to reach a conclusion about a causal relationship between exposure to PFOA and PFOS and any immune-related health condition in humans. When interpreting such studies, an immunodeficiency should not be presumed to exist when there is no evidence of a clinical abnormality. Large, prospective studies with repeated exposure assessment in independent populations are needed to confirm some suggestive associations with certain endpoints.


Asunto(s)
Ácidos Alcanesulfónicos/envenenamiento , Caprilatos/envenenamiento , Exposición a Riesgos Ambientales/estadística & datos numéricos , Fluorocarburos/envenenamiento , Enfermedades del Sistema Inmune/epidemiología , Ácidos Alcanesulfónicos/toxicidad , Animales , Asma/inducido químicamente , Asma/epidemiología , Caprilatos/toxicidad , Fluorocarburos/toxicidad , Humanos , Sistema Inmunológico/efectos de los fármacos , Enfermedades del Sistema Inmune/inducido químicamente , Inmunotoxinas/envenenamiento , Inmunotoxinas/toxicidad
7.
Am J Epidemiol ; 181(6): 374-84, 2015 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-25731889

RESUMEN

We systematically evaluated studies published through May 2014 in which investigators assessed the dose-response relationship between serum levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the occurrence of diabetes mellitus (DM), and we investigated the extent and sources of interstudy heterogeneity. The dose-response relationship between serum TCDD and DM across studies was examined using 2 dependent variables: an exposure level-specific proportion of persons with DM and a corresponding natural log-transformed ratio measure of the association between TCDD and DM. Regression slopes for each dependent variable were obtained for each study and included in a random-effects meta-analysis. Sensitivity analyses were used to assess the influence of inclusion and exclusion decisions, and sources of heterogeneity were explored using meta-regression models and a series of subanalyses. None of the summary estimates in the main models or in the sensitivity analyses indicated a statistically significant association. We found a pronounced dichotomy: a positive dose-response in cross-sectional studies of populations with low-level TCDD exposures (serum concentrations <10 pg/g lipid) and heterogeneous, but on balance null, results for prospective studies of persons with high prediagnosis TCDD body burdens. Considering the discrepancy of results for low current versus high past TCDD levels, the available data do not indicate that increasing TCDD exposure is associated with an increased risk of DM.


Asunto(s)
Diabetes Mellitus/sangre , Diabetes Mellitus/epidemiología , Contaminantes Ambientales/sangre , Dibenzodioxinas Policloradas/sangre , Relación Dosis-Respuesta a Droga , Exposición a Riesgos Ambientales , Humanos , Incidencia , Prevalencia
8.
Crit Rev Toxicol ; 44(5): 436-49, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24766058

RESUMEN

OBJECTIVE: We investigated whether available epidemiological and toxicological data suggest an increased risk of mesothelioma among workers exposed to synthetic vitreous fibers (SVF). METHODS: We conducted a systematic review of epidemiological studies on the risk of mesothelioma among workers exposed to SVF, and toxicological studies on SVF and mesothelioma. RESULTS: Seven cohort studies were conducted among workers employed in production of rock/slag wool, glass wool, or continuous glass filament in the United States, Canada, and Europe. Of the six deaths from mesothelioma identified in these studies, three had exposure to asbestos. A review of death certificates in a study of rock wool production workers identified one additional probable death. A formal comparison with expected deaths is not feasible. Four community-based case-control studies were identified, of which three reported an increased risk among SVF-exposed workers. The number of cases not exposed to asbestos was less, and residual confounding from asbestos exposure misclassification may explain the association in these studies. The toxicology review of SVF suggested that they present a low hazard mostly due to their low biopersistence, typically with a half-life in rat studies of tens of days compared to amphibole asbestos which has a half-life of 400-500 days. CONCLUSIONS: The combined evidence from epidemiology and toxicology provide little evidence that exposure to SVF increases the risk of mesothelioma.


Asunto(s)
Amianto/toxicidad , Mesotelioma/epidemiología , Mesotelioma/patología , Fibras Minerales/toxicidad , Exposición Profesional/efectos adversos , Animales , Canadá/epidemiología , Modelos Animales de Enfermedad , Europa (Continente)/epidemiología , Semivida , Humanos , Incidencia , Mesotelioma/etiología , Ratas , Medición de Riesgo , Pruebas de Toxicidad , Estados Unidos/epidemiología
9.
Crit Rev Toxicol ; 44 Suppl 1: 1-81, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24793953

RESUMEN

Perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) are ubiquitous synthetic chemicals with no known effect on human cancer development. This article systematically and critically reviews the epidemiologic evidence regarding the association between PFOA and PFOS exposure and cancer risk in humans. Eighteen epidemiologic studies - eight of PFOA, four of PFOS, and six of both PFOA and PFOS - have estimated associations of exposure to these chemicals with cancer incidence or mortality, with studies equally divided between occupational and nonoccupational settings. Although some statistically significant positive associations have been reported, for example, with cancers of the prostate, kidney, testis, and thyroid, the majority of relative risk estimates for both PFOA and PFOS have been between 0.5 and 2.0 (with 95% confidence intervals including 1.0), inconsistently detected across studies, counterbalanced by negative associations, not indicative of a monotonic exposure-response relationship, and not coherent with toxicological evidence in animals, in which the primary target organs are the liver, testis (Leydig cells), and pancreas (acinar cells). Many positive associations with PFOA exposure were detected in community settings without occupational exposure and were not supported by results in exposed workers. Given that occupational exposure to PFOA and PFOS is one to two orders of magnitude higher than environmental exposure, the discrepant positive findings are likely due to chance, confounding, and/or bias. Taken together, the epidemiologic evidence does not support the hypothesis of a causal association between PFOA or PFOS exposure and cancer in humans.


Asunto(s)
Ácidos Alcanesulfónicos/toxicidad , Caprilatos/toxicidad , Fluorocarburos/toxicidad , Neoplasias/epidemiología , Animales , Exposición a Riesgos Ambientales/efectos adversos , Humanos , Neoplasias/etiología , Neoplasias/patología , Exposición Profesional/efectos adversos , Riesgo
10.
Crit Rev Toxicol ; 44(5): 450-66, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24766059

RESUMEN

Geographic modeling is increasingly being used to estimate long-term environmental exposures in epidemiologic studies of chronic disease outcomes. However, without validation against measured environmental concentrations, personal exposure levels, or biologic doses, these models cannot be assumed a priori to be accurate. This article discusses three examples of epidemiologic associations involving exposures estimated using geographic modeling, and identifies important issues that affect geographically modeled exposure assessment in these areas. In air pollution epidemiology, geographic models of fine particulate matter levels have frequently been validated against measured environmental levels, but comparisons between ambient and personal exposure levels have shown only moderate correlations. Estimating exposure to magnetic fields by using geographically modeled distances is problematic because the error is larger at short distances, where field levels can vary substantially. Geographic models of environmental exposure to pesticides, including paraquat, have seldom been validated against environmental or personal levels, and validation studies have yielded inconsistent and typically modest results. In general, the exposure misclassification resulting from geographic models of environmental exposures can be differential and can result in bias away from the null even if non-differential. Therefore, geographic exposure models must be rigorously constructed and validated if they are to be relied upon to produce credible scientific results to inform epidemiologic research. To our knowledge, such models have not yet successfully predicted an association between an environmental exposure and a chronic disease outcome that has eventually been established as causal, and may not be capable of doing so in the absence of thorough validation.


Asunto(s)
Exposición a Riesgos Ambientales/análisis , Modelos Teóricos , Contaminantes Atmosféricos/análisis , Contaminación del Aire/análisis , Niño , Geografía , Humanos , Leucemia/etiología , Leucemia/patología , Paraquat/análisis , Paraquat/toxicidad , Material Particulado/análisis , Reproducibilidad de los Resultados
11.
Eur J Epidemiol ; 29(10): 667-723, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25064616

RESUMEN

To inform risk assessment and regulatory decision-making, the relationship between 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and prostate cancer requires clarification. This article systematically and critically reviews the epidemiologic evidence on the association between exposure to TCDD or Agent Orange, a TCDD-contaminated herbicide used during the Vietnam War, and prostate cancer risk. Articles evaluated include 11 studies of three cohorts, four case-control or cross-sectional studies, and three case-only studies of military veterans with information on estimated Agent Orange or TCDD exposure; 13 studies of seven cohorts, one case-control study, and eight proportionate morbidity or mortality studies of Vietnam veterans without information on Agent Orange exposure; 11 cohort studies of workers with occupational exposure to TCDD; and two studies of one community cohort with environmental exposure to TCDD. The most informative studies, including those of Vietnam veterans involved in Agent Orange spraying or other handling, herbicide manufacturing or spraying workers with occupational TCDD exposure, and community members exposed to TCDD through an industrial accident, consistently reported no significant increase in prostate cancer incidence or mortality. Only some potentially confounded studies of Vietnam veterans compared with the general population, studies with unreliable estimates of Agent Orange exposure, and analyses of selected subgroups of Vietnam veterans reported positive associations. Overall, epidemiologic research offers no consistent or convincing evidence of a causal relationship between exposure to Agent Orange or TCDD and prostate cancer. More accurate exposure assessment is needed in large epidemiologic studies to rule out a causal association more conclusively.


Asunto(s)
Ácido 2,4,5-Triclorofenoxiacético/efectos adversos , Ácido 2,4-Diclorofenoxiacético/efectos adversos , Exposición a Riesgos Ambientales , Dibenzodioxinas Policloradas/efectos adversos , Neoplasias de la Próstata/inducido químicamente , Neoplasias de la Próstata/epidemiología , Medición de Riesgo , Agente Naranja , Contaminantes Ambientales , Estudios Epidemiológicos , Humanos , Masculino , Personal Militar , Veteranos
12.
Birth Defects Res B Dev Reprod Toxicol ; 101(3): 215-36, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24797711

RESUMEN

Atrazine (ATR) is a commonly used agricultural herbicide that has been the subject of epidemiologic studies assessing its relation to reproductive health problems. This review evaluates both the consistency and the quality of epidemiologic evidence testing the hypothesis that ATR exposure, at usually encountered levels, is a risk factor for birth defects, small for gestational age birth weight, prematurity, miscarriages, and problems of fetal growth and development. We followed the current methodological guidelines for systematic reviews by using two independent researchers to identify, retrieve, and evaluate the relevant epidemiologic literature on the relation of ATR to various adverse outcomes of birth and pregnancy. Each eligible paper was summarized with respect to its methods and results with particular attention to study design and exposure assessment, which have been cited as the main areas of weakness in ATR research. As a quantitative meta-analysis was not feasible, the study results were categorized qualitatively as positive, null, or mixed. The literature on ATR and pregnancy-related health outcomes is growing rapidly, but the quality of the data is poor with most papers using aggregate rather than individual-level information. Without good quality data, the results are difficult to assess; however, it is worth noting that none of the outcome categories demonstrated consistent positive associations across studies. Considering the poor quality of the data and the lack of robust findings across studies, conclusions about a causal link between ATR and adverse pregnancy outcomes are not warranted.


Asunto(s)
Atrazina/toxicidad , Resultado del Embarazo , Aborto Espontáneo/inducido químicamente , Aborto Espontáneo/patología , Animales , Peso al Nacer/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Desarrollo Fetal/efectos de los fármacos , Edad Gestacional , Herbicidas/toxicidad , Humanos , Exposición Materna/efectos adversos , Embarazo
13.
Occup Environ Med ; 70(2): 73-80, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23104734

RESUMEN

OBJECTIVES: Occupational exposure to chlorinated aliphatic solvents has been associated with an increased cancer risk, including brain cancer. However, many of these solvents remain in active, large-volume use. We evaluated glioma risk from non-farm occupational exposure (ever/never and estimated cumulative exposure) to any of the six chlorinated solvents--carbon tetrachloride, chloroform, methylene chloride, trichloroethylene, tetrachloroethylene or 1,1,1--trichloroethane-among 798 cases and 1175 population-based controls, aged 18-80 years and non-metropolitan residents of Iowa, Michigan, Minnesota and Wisconsin. Methods Solvent use was estimated based on occupation, industry and era, using a bibliographic database of published exposure levels and exposure determinants. Unconditional logistic regression was used to calculate ORs adjusted for frequency matching variables age group and sex, and age and education. Additional analyses were limited to 904 participants who donated blood specimens (excluding controls reporting a previous diagnosis of cancer) genotyped for glutathione-S-transferases GSTP1, GSTM3 and GSTT1. Individuals with functional GST genes might convert chlorinated solvents crossing the blood-brain barrier into cytotoxic metabolites. RESULTS: Both estimated cumulative exposure (ppm-years) and ever exposure to chlorinated solvents were associated with decreased glioma risk and were statistically significant overall and for women. In analyses comparing participants with a high probability of exposure with the unexposed, no associations were statistically significant. Solvent-exposed participants with functional GST genes were not at increased risk of glioma. CONCLUSIONS: We observed no associations of glioma risk and chlorinated solvent exposure. Large pooled studies are needed to explore the interaction of genetic pathways and environmental and occupational exposures in glioma aetiology.


Asunto(s)
Neoplasias Encefálicas/inducido químicamente , Glioma/inducido químicamente , Hidrocarburos Clorados/toxicidad , Exposición Profesional/efectos adversos , Solventes/toxicidad , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/genética , Estudios de Casos y Controles , Femenino , Eliminación de Gen , Genotipo , Glioma/epidemiología , Glioma/genética , Glutatión Transferasa/genética , Humanos , Masculino , Persona de Mediana Edad , Medio Oeste de Estados Unidos/epidemiología , Polimorfismo Genético/genética , Factores de Riesgo , Adulto Joven
14.
Crit Rev Toxicol ; 42(2): 107-18, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22276590

RESUMEN

There is controversy on whether occupational exposure to beryllium causes lung cancer. We conducted a systematic review of epidemiologic studies on cancer among workers exposed to beryllium, including a study of seven U.S. production plants which has been recently updated, a study of patients with beryllium disease (largely overlapping with the former study) and several smaller studies. A small excess mortality from lung cancer was detected in the large cohort, which was partially explained by confounding by tobacco smoking and urban residence. Other potential confounders have not been addressed. The excess mortality was mainly among workers employed (often for a short duration) in the early phase of the manufacturing industry. There was no relation with duration of employment or cumulative exposure, whereas average and maximum exposure were associated with lung cancer risk. The use of lagged exposure variables resulted in associations with lung cancer risk; however, these associations were due to confounding by year of birth and year of hire. The studies of beryllium disease patients do not provide independent evidence and the results from other studies do not support the hypothesis of an increased risk of lung cancer or any other cancer. Overall, the available evidence does not support a conclusion that a causal association has been established between occupational exposure to beryllium and the risk of cancer.


Asunto(s)
Beriliosis/epidemiología , Berilio/toxicidad , Neoplasias Pulmonares/mortalidad , Enfermedades Profesionales/epidemiología , Exposición Profesional/efectos adversos , Beriliosis/fisiopatología , Estudios Epidemiológicos , Humanos , Industrias , Neoplasias Pulmonares/inducido químicamente , Enfermedades Profesionales/inducido químicamente , Factores de Riesgo , Fumar/efectos adversos , Factores de Tiempo
15.
Environ Health ; 11: 39, 2012 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-22691464

RESUMEN

BACKGROUND: An excess incidence of brain cancer in farmers has been noted in several studies. The National Institute for Occupational Safety and Health developed the Upper Midwest Health Study (UMHS) as a case-control study of intracranial gliomas and pesticide uses among rural residents. Previous studies of UMHS participants, using "ever-never" exposure to farm pesticides and analyzing men and women separately, found no positive association of farm pesticide exposure and glioma risks. The primary objective was to determine if quantitatively estimated exposure of pesticide applicators was associated with an increased risk of glioma in male and female participants. METHODS: The study included 798 histologically confirmed primary intracranial glioma cases (45 % with proxy respondents) and 1,175 population-based controls, all adult (age 18-80) non-metropolitan residents of Iowa, Michigan, Minnesota, and Wisconsin. The analyses used quantitatively estimated exposure from questionnaire responses evaluated by an experienced industrial hygienist with 25 years of work on farm pesticide analyses. Odds ratios (ORs) and 95 % confidence intervals (CIs) using unconditional logistic regression modeling were calculated adjusting for frequency-matching variables (10-year age group and sex), and for age and education (a surrogate for socioeconomic status). Analyses were separately conducted with or without proxy respondents. RESULTS: No significant positive associations with glioma were observed with cumulative years or estimated lifetime cumulative exposure of farm pesticide use. There was, a significant inverse association for phenoxy pesticide used on the farm (OR 0.96 per 10 g-years of cumulative exposure, CI 0.93-0.99). No significant findings were observed when proxy respondents were excluded. Non-farm occupational applicators of any pesticide had decreased glioma risk: OR 0.72, CI 0.52-0.99. Similarly, house and garden pesticide applicators had a decreased risk of glioma: OR 0.79, CI 0.66-0.93, with statistically significant inverse associations for use of 2,4-D, arsenates, organophosphates, and phenoxys. CONCLUSIONS: These results are consistent with our previous findings for UMHS of reported farm pesticide exposure and support a lack of positive association between pesticides and glioma.


Asunto(s)
Enfermedades de los Trabajadores Agrícolas/epidemiología , Neoplasias Encefálicas/epidemiología , Glioma/epidemiología , Exposición Profesional , Plaguicidas/toxicidad , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades de los Trabajadores Agrícolas/inducido químicamente , Neoplasias Encefálicas/inducido químicamente , Estudios de Casos y Controles , Exposición a Riesgos Ambientales , Femenino , Glioma/inducido químicamente , Encuestas Epidemiológicas , Humanos , Incidencia , Modelos Logísticos , Masculino , Persona de Mediana Edad , Medio Oeste de Estados Unidos/epidemiología , Oportunidad Relativa , Medición de Riesgo , Adulto Joven
16.
Regul Toxicol Pharmacol ; 64(1): 186-8, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22810056

RESUMEN

This study evaluates the National Toxicology Program's Report on Carcinogens program (RoCP) and compares it with the International Agency for Research on Cancer Monographs Program (IMP). We tracked agents classified in the RoCP since 1983 as known human carcinogens (A-List), or as reasonably anticipated to be human carcinogens (B-List). The first A-list included 24 agents, and twenty-four unique agents were added in the following 28years; twenty were listed by IMP as Group 1 (carcinogenic to humans) 7years before their A-list appearance. Group 1 also includes 30 or more agents eligible for, but not on, the A-list. The first B-list included 98 agents, and this increased to 185. Of these, 39 are in Group 2A (probably carcinogenic), and 122 are in Group 2B (possibly carcinogenic). Only 5% of the 204 agents ever on the B-list have been upgraded to the A-list. The RoCP is severely limited because it evaluates few agents and because its B-list does not distinguish between probable and possible human carcinogens. Further, it mislabels likely non-carcinogens as reasonably anticipated to be carcinogens. If the RoCP were terminated there would be no loss or delay of information available to scientific, public health and regulatory communities.


Asunto(s)
Pruebas de Carcinogenicidad/métodos , Carcinógenos Ambientales/toxicidad , Neoplasias/inducido químicamente , Xenobióticos/toxicidad , Animales , Carcinógenos Ambientales/clasificación , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Ratones , Ratas , Medición de Riesgo , Especificidad de la Especie , Organización Mundial de la Salud , Xenobióticos/clasificación
17.
Regul Toxicol Pharmacol ; 63(3): 440-52, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22683395

RESUMEN

The United States Environmental Protection Agency and other regulatory agencies around the world have registered glyphosate as a broad-spectrum herbicide for use on multiple food and non-food use crops. Glyphosate is widely considered by regulatory authorities and scientific bodies to have no carcinogenic potential, based primarily on results of carcinogenicity studies of rats and mice. To examine potential cancer risks in humans, we reviewed the epidemiologic literature to evaluate whether exposure to glyphosate is associated causally with cancer risk in humans. We also reviewed relevant methodological and biomonitoring studies of glyphosate. Seven cohort studies and fourteen case-control studies examined the association between glyphosate and one or more cancer outcomes. Our review found no consistent pattern of positive associations indicating a causal relationship between total cancer (in adults or children) or any site-specific cancer and exposure to glyphosate. Data from biomonitoring studies underscore the importance of exposure assessment in epidemiologic studies, and indicate that studies should incorporate not only duration and frequency of pesticide use, but also type of pesticide formulation. Because generic exposure assessments likely lead to exposure misclassification, it is recommended that exposure algorithms be validated with biomonitoring data.


Asunto(s)
Glicina/análogos & derivados , Herbicidas/toxicidad , Neoplasias/epidemiología , Estudios de Casos y Controles , Estudios de Cohortes , Glicina/toxicidad , Humanos , Glifosato
18.
Am J Ind Med ; 55(9): 747-55, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22715102

RESUMEN

BACKGROUND: Understanding glioma etiology requires determining which environmental factors are associated with glioma. Upper Midwest Health Study case-control participant work histories collected 1995-1998 were evaluated for occupational associations with glioma. "Exposures of interest" from our study protocol comprise our a priori hypotheses. MATERIALS AND METHODS: Year-long or longer jobs for 1,973 participants were assigned Standard Occupational Classifications (SOC) and Standard Industrial Classifications (SIC). The analysis file includes 8,078 SIC- and SOC-coded jobs. For each individual, SAS 9.2 programs collated employment with identical SIC-SOC coding. Distributions of longest "total employment duration" (total years worked in jobs with identical industry and occupation codes, including multiple jobs, and non-consecutive jobs) were compared between cases and controls, using an industrial hygiene algorithm to group occupations. RESULTS: Longest employment duration was calculated for 780 cases and 1,156 controls. More case than control longest total employment duration was in the "engineer, architect" occupational group [16 cases, 10 controls, odds ratio (OR) 2.50, adjusted for age group, sex, age and education, 95% confidence interval (CI) 1.12-5.60]. Employment as a food processing worker [mostly butchers and meat cutters] was of borderline significance (27 cases, 21 controls, adjusted OR: 1.78, CI: 0.99-3.18). CONCLUSIONS: Among our exposures of interest work as engineers or as butchers and meat cutters was associated with increased glioma risk. Significant associations could be due to chance, because of multiple comparisons, but similar findings have been reported for other glioma studies. Our results suggest some possible associations but by themselves could not provide conclusive evidence.


Asunto(s)
Neoplasias Encefálicas/etiología , Glioma/etiología , Enfermedades Profesionales/etiología , Exposición Profesional/efectos adversos , Enfermedades de los Trabajadores Agrícolas/etiología , Estudios de Casos y Controles , Femenino , Industria de Procesamiento de Alimentos , Encuestas Epidemiológicas , Humanos , Masculino , Medio Oeste de Estados Unidos , Exposición Profesional/estadística & datos numéricos , Estudios Retrospectivos , Factores de Riesgo , Población Rural , Encuestas y Cuestionarios , Factores de Tiempo
19.
Crit Rev Toxicol ; 41(7): 622-36, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21718216

RESUMEN

The authors reviewed the epidemiologic studies on exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and cancer risk, published since the last full-scale review made by the International Agency for Research on Cancer Monographs program in 1997. The update of a cohort of US herbicide producers generated negative results overall; the internal analysis provided evidence of an increased "all-cancer" risk in the highest exposure category, with a statistically significant exposure-response association in some of the many analyses performed. The update of a similar Dutch cohort did not confirm the previously observed association with TCDD exposure. The updated surveillance of the Seveso population provided evidence of increased all-cancer mortality 15-20 years after exposure among those living in the most contaminated area but might also reflect random variation, as overall excesses in the most recent follow-up were not observed. Corresponding data on cancer incidence offer little support to the mortality results. Updated results from cohort studies of Vietnam veterans potentially exposed to TCDD did not consistently suggest an increased risk of cancer. Results of additional, smaller studies of other occupational groups potentially exposed to TCDD, and of community-based case-control studies, did not provide consistent evidence of an increased cancer risk. In conclusion, recent epidemiological evidence falls far short of conclusively demonstrating a causal link between TCDD exposure and cancer risk in humans. The emphasis on results for overall cancer risk-rather than risk for specific neoplasms-is not justified on epidemiologic grounds and is not a reason for ignoring the weaknesses of the available evidence.


Asunto(s)
Carcinógenos Ambientales/toxicidad , Herbicidas/toxicidad , Neoplasias/inducido químicamente , Neoplasias/epidemiología , Dibenzodioxinas Policloradas/toxicidad , Animales , Sesgo , Carcinógenos Ambientales/administración & dosificación , Causalidad , Factores de Confusión Epidemiológicos , Herbicidas/administración & dosificación , Humanos , Dibenzodioxinas Policloradas/administración & dosificación , Reproducibilidad de los Resultados , Riesgo
20.
Regul Toxicol Pharmacol ; 61(2): 172-84, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21798302

RESUMEN

The United States (US) Environmental Protection Agency (EPA) and other regulatory agencies around the world have registered glyphosate as a broad-spectrum herbicide for use on multiple food and non-food use crops. To examine potential health risks in humans, we searched and reviewed the literature to evaluate whether exposure to glyphosate is associated causally with non-cancer health risks in humans. We also reviewed biomonitoring studies of glyphosate to allow for a more comprehensive discussion of issues related to exposure assessment and misclassification. Cohort, case-control and cross-sectional studies on glyphosate and non-cancer outcomes evaluated a variety of endpoints, including non-cancer respiratory conditions, diabetes, myocardial infarction, reproductive and developmental outcomes, rheumatoid arthritis, thyroid disease, and Parkinson's disease. Our review found no evidence of a consistent pattern of positive associations indicating a causal relationship between any disease and exposure to glyphosate. Most reported associations were weak and not significantly different from 1.0. Because accurate exposure measurement is crucial for valid results, it is recommended that pesticide-specific exposure algorithms be developed and validated.


Asunto(s)
Exposición a Riesgos Ambientales/efectos adversos , Exposición a Riesgos Ambientales/estadística & datos numéricos , Glicina/análogos & derivados , Herbicidas/envenenamiento , Animales , Estudios de Casos y Controles , Estudios de Cohortes , Estudios Transversales , Glicina/envenenamiento , Glicina/toxicidad , Herbicidas/toxicidad , Humanos , Medición de Riesgo/métodos , Estados Unidos/epidemiología , United States Environmental Protection Agency , Glifosato
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA